8-K: CV Sciences Reports First Quarter 2025 Financial Results, Launches New Plant-Based Product Line

CV Sciences, Inc. announced its Q1 2025 financial results, including revenue of $3.6 million and the launch of its new plant-based product line, Lunar Fox.

Summary

• CV Sciences, Inc. reported its financial results for the quarter ended March 31, 2025.
• The company generated revenue of $3.6 million in Q1 2025, compared to $4.0 million in Q1 2024 and $3.9 million in Q4 2024.
• Gross margin was 46.0% for Q1 2025, compared to 46.3% for Q1 2024 and 43.2% for Q4 2024.
• The company's cash balance at the end of the quarter was $0.8 million, up from $0.5 million at the end of 2024.
• Adjusted EBITDA loss improved to $0.3 million for Q1 2025, compared to $0.5 million for Q1 2024 and $0.4 million for Q4 2024.
• CV Sciences entered into a financing agreement with an institutional investor, resulting in net proceeds of $1.2 million.
• The company launched a new plant-based company and product line called Lunar Fox, featuring vegan alternatives to traditional animal-based proteins.
• 35% of net revenue for the first quarter 2025 was from new products launched since January 1, 2023.
• During this time period, the company launched 34 new products.
• The company generated an operating income of $11,000 in the first quarter 2025, compared to an operating loss of $0.6 million in the first quarter 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While revenue decreased, the company improved its EBITDA loss, increased its cash balance, and launched a new product line. The management's comments are optimistic about future growth and profitability.

Positives

• Gross margins remain healthy at 46% and are expected to improve further in the second half of 2025.
• Adjusted EBITDA loss improved by 40% compared to the same quarter last year.
• The company secured $1.2 million in financing.
• The launch of the Lunar Fox product line diversifies the company's offerings and targets a growing market.
• Operating income improved to $11,000 in Q1 2025, compared to an operating loss of $0.6 million in Q1 2024.
• Cash balance increased from $0.5 million to $0.8 million.

Negatives

• Revenue decreased by 10% compared to the first quarter of 2024, from $4.0 million to $3.6 million.
• The decline in revenue is primarily due to lower sales volume, with a decrease of 11.8% in total units sold.
• The company still reported an adjusted EBITDA loss of $0.3 million for the quarter.
• The company had a net loss of $109,000.

Risks

• The company faces challenges related to the uncertain state regulatory environment for the CBD category.
• Forward-looking statements involve risks, uncertainties, and assumptions that are difficult to predict, and actual outcomes may differ materially.
• The company's reliance on new product development and M&A opportunities to improve top-line revenue, profitability, and shareholder value carries inherent risks.

Future Outlook

The company anticipates further gross margin improvements in the second half of 2025 and is working to achieve organic growth through new product development and M&A opportunities to improve top-line revenue, profitability, and cash flow. The company also looks forward to a more balanced product portfolio through further new product development and M&A opportunities that will help to improve top-line revenue, profitability and shareholder value.

Management Comments

• 'We are pleased with our first quarter 2025 results,' stated Joseph Dowling, Chief Executive Officer of CV Sciences.
• Joseph Dowling stated that the company's gross margins remain very healthy at 46% and they anticipate further gross margin improvements in the second half of 2025.
• Joseph Dowling stated that they are working diligently to achieve organic growth through new product development while continuing to pursue additional M&A opportunities to improve their top-line revenue, profitability and cash flow.
• Joseph Dowling stated that their gross margin and adjusted EBITDA progress demonstrates their cost-efficient execution as they move closer to profitability and positive cash flow.
• Joseph Dowling stated that they are also making good progress on in-sourcing production of many of their current products through their acquisition of Elevated Softgels, which will help to further improve their gross margin over time.
• Joseph Dowling stated that their continuous commitment to innovation will diversify their product offering and help mitigate some of the challenges they face with the uncertain state regulatory environment for the CBD category.

Industry Context

CV Sciences' launch of Lunar Fox reflects the growing trend of plant-based alternatives in the food industry, driven by increasing consumer demand for vegan and flexitarian options. The company's focus on nutraceuticals and hemp extracts aligns with the expanding wellness market, but it faces regulatory challenges in the CBD sector.

Comparison to Industry Standards

• Comparing CV Sciences' performance to industry peers in the nutraceutical and CBD sectors is challenging without specific competitor data in this release.
• However, the company's gross margin of 46% could be compared to companies like Charlotte's Web or cbdMD, if their gross margins are publicly available.
• The success of Lunar Fox can be benchmarked against established plant-based food companies like Beyond Meat or Impossible Foods, focusing on market penetration and consumer adoption rates.
• The company's adjusted EBITDA loss improvement can be compared to other companies in the sector that are also working towards profitability.

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue but encouraged by the improved EBITDA loss and new product launch.
• Employees may be affected by the company's efforts to improve profitability and pursue M&A opportunities.
• Customers may benefit from the new Lunar Fox product line and the company's commitment to innovation.
• Suppliers may be impacted by changes in the company's product mix and sourcing strategies.
• Creditors may be reassured by the company's improved financial performance and increased cash balance.

Next Steps

• The company will host a conference call and webcast to discuss these results today at 4:00 pm EDT/1:00 pm PDT.
• The company will continue to pursue organic growth through new product development.
• The company will continue to pursue additional M&A opportunities to improve top-line revenue, profitability and cash flow.

Key Dates

Keywords

financial results, CBD, hemp extracts, plant-based foods, Lunar Fox, CV Sciences, revenue, EBITDA, gross margin